Overview

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Status:
Terminated
Trial end date:
2020-04-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy
Phase:
Phase 1
Details
Lead Sponsor:
Reneo Pharma Ltd